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Axonal	degeneration	is	an	important	determinant	of	progressive	neurological	disability	in	multiple	sclerosis	
(MS).	Thus,	therapeutic	approaches	promoting	neuroprotection	could	aid	the	treatment	of	progressive	MS.	
Here,	we	used	what	we	believe	is	a	novel	water-soluble	fullerene	derivative	(ABS-75)	attached	to	an	NMDA	recep-
tor	antagonist,	which	combines	antioxidant	and	anti-excitotoxic	properties,	to	block	axonal	damage	and	reduce	
disease	progression	in	a	chronic	progressive	EAE	model.	Fullerene	ABS-75	treatment	initiated	after	disease	
onset	reduced	the	clinical	progression	of	chronic	EAE	in	NOD	mice	immunized	with	myelin-oligodendrocyte	
glycoprotein	(MOG).	Reduced	disease	progression	in	ABS-75–treated	mice	was	associated	with	reduced	axonal	
loss	and	demyelination	in	the	spinal	cord.	Fullerene	ABS-75	halted	oxidative	injury,	CD11b+	infiltration,	and	
CCL2	expression	in	the	spinal	cord	of	mice	without	interfering	with	antigen-specific	T	cell	responses.	In	vitro,	
fullerene	ABS-75	protected	neurons	from	oxidative	and	glutamate-induced	injury	and	restored	glutamine	syn-
thetase	and	glutamate	transporter	expression	in	astrocytes	under	inflammatory	insult.	Glutamine	synthetase	
expression	was	also	increased	in	the	white	matter	of	fullerene	ABS-75–treated	animals.	Our	data	demonstrate	
the	neuroprotective	effect	of	treatment	with	a	fullerene	compound	combined	with	a	NMDA	receptor	antago-
nist,	which	may	be	useful	in	the	treatment	of	progressive	MS	and	other	neurodegenerative	diseases.
Introduction
Epidemiologic studies show that approximately 85% of patients 
with MS initially develop a relapsing-remitting form of the dis-
ease (1, 2). However, within 10 years, approximately half of those 
with relapsing-remitting MS (RR-MS) develop secondary progres-
sive MS (SP-MS) (3). In this stage there are few, if any, attacks and 
the patients progress and accumulate neurological disability. An 
understanding of the factors associated with disease progression 
and the development of treatments to control them are crucial 
goals in MS research. The reversible nature of inflammation and 
demyelination, which are the hallmarks of RR-MS, does not fully 
explain why there is a transition to SP-MS. Moreover, treatments 
which halt the inflammatory response do not always stop disease 
progression and cumulative neurological disability.
Recent evidence supports the view that axonal degeneration may 
be a major determinant of progressive neurological disability in 
patients with MS (4–6). Therefore, the development of new thera-
peutic approaches designed for neuroprotection, and ultimately 
at preventing or delaying neurological disability, would be of great 
benefit for MS patients. Because increased oxidative stress and 
imbalanced glutamate metabolism can lead to axonal degenera-
tion (7–12) and are associated with relapses and disease progres-
sion in MS (13, 14), it has been suggested that antioxidants and 
glutamate receptor (NMDA and AMPA/kainate) antagonists are 
agents worthy of investigation for the neurodegenerative compo-
nent of a disease such as MS (15–20).
In this study we employed a model in which myelin-oligoden-
drocyte glycoprotein–immunized (MOG-immunized) NOD mice 
develop chronic progressive EAE to test a C60-fullerene derivative 
as what we believe to be a novel therapeutic approach to confer 
neuroprotection and reduce disease progression.
Fullerenes are an allotropic form of carbon which were observed 
for the first time in 1985 and isolated in 1990 (21). They consist 
of a molecule composed of 60 carbon atoms that form a hollow 
sphere 1 nanometer in diameter (21, 22). Water-soluble carboxy-
fullerenes have been described to possess robust neuroprotective 
effects against excitotoxic, apoptotic, and metabolic insults in cor-
tical cell cultures and, in some in vivo models, have been shown to 
protect against stroke (23–29). The neuroprotective effect of fuller-
enes has been attributed to their redox properties and high affinity 
toward free radicals, as C60 is capable of being reversibly reduced by 
up to 6 electrons. Moreover, the addition of as many as 34 methyl 
radicals to a C60 sphere has been reported, leading C60 to be char-
acterized as a “radical sponge” (30). These unique properties of 
the fullerenes provide an excellent platform for development of 
novel neuroprotecting agents. Here we used a fullerene derivative 
termed “ABS-75” (31).
Our strategy was to develop receptor-specific antioxidant ther-
apy. Fullerene ABS-75 is the first example of a water-soluble ada-
mantyl-oligoethyleneglycol-fullerene hybrid, in which NMDA 
receptor–targeting (antagonist) adamantyl groups are connected 
to an antioxidant carboxyfullerene moiety via oligoethylenegly-
col bridges (see Figure 1A). Adamantane family members are well 
known NMDA antagonists and have been shown to block NMDA 
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receptors containing either NR2A, NR2B or NR2D subunits (32). 
In addition to water solubility, incorporation of biocompatible 
and flexible oligoethyleneglycol bridges between the 2 func-
tional moieties resulted in improved NMDA receptor affinity, 
since receptor-binding moieties are not sterically hindered by 
the fullerene fragment.
ABS-75 is a derivative of carboxyl-functionalized fullerenes, and it 
has been shown that carboxyl-functionalized fullerenes efficiently 
cross the blood-brain barrier (33). Furthermore, ABS-75 is con-
siderably more hydrophobic than most carboxyl-functionalized 
fullerenes, and in contrast to negatively charged carboxyl-function-
alized fullerenes, ABS-75 is a neutral molecule. We hypothesized 
that these features would further enhance the ability of ABS-75 
to cross the blood-brain barrier. In addition, a leaky blood-brain 
barrier is a feature of EAE, which would further facilitate ABS-75 
penetration into the brain.
Prior studies of antioxidant targeting focused on delivery of anti-
oxidants to mitochondria (34, 35). To our knowledge, although 
many compounds function as NMDA receptor antagonists (36), 
targeting an antioxidant functional moiety to the NMDA receptor 
has not been reported. Here we show that combining the antioxi-
dant properties of fullerene with the anti-excitotoxic properties of 
an NMDA receptor antagonist in a single molecule was effective 
in blocking axonal damage and reducing disease progression in a 
chronic progressive EAE model.
Results
Fullerene ABS-75 treatment initiated after disease onset reduces EAE pro-
gression in the chronic progressive NOD EAE model. In order to inves-
tigate the neuroprotective effects of fullerene ABS-75 (Figure 1A), 
we induced chronic progressive EAE by immunizing NOD mice 
with MOG35–55. When 10-week-old NOD mice were immunized 
with MOG35–55 in CFA, the first signs of disease appeared at days 
11–12 (peaking at days 16–18), and after partial recovery from this 
initial acute attack, there was a progressively worsening relapse 
without full remission. This was then followed by a secondary 
progressive course characterized by chronic clinical impairment 
(Figure 1B). This model was chosen because it appeared to be an 
excellent model for acute MS followed by a progressive chronic 
phase associated with neurological disability.
Fullerene ABS-75 (30 μg/kg, i.p.) was given daily from day 20 
(after the animals recovered from the first peak of disease) to the 
end of the experiment at day 70. We found that ABS-75 treatment 
initiated after disease onset reduced EAE progression. Fullerene 
ABS-75–treated mice had a lower mean clinical score in the mid 
phase (days 31–34) of the disease course and also by the end of the 
disease course as compared with vehicle-treated animals (Figure 
1B and Table 1). Two-way ANOVA also revealed that there was a 
strong effect of the treatment on disease course. Thus, disease pro-
gression was significantly reduced in the fullerene-treated group 
as compared with vehicle-treated group (F = 271.68, P < 0.0001). 
Figure 1
Fullerene ABS-75 treatment reduces disease 
progression in secondary progressive EAE. (A) 
Fullerene ABS-75 consists of the C60 fullerene 
core (i) attached to 4 adamantyl groups (ii) by 
oligoethyleneglycol bridges (iii). (B) Chronic pro-
gressive EAE was induced in 10-week-old NOD 
mice by subcutaneous immunization with 150 μg 
of MOG35–55 peptide in 4 mg/ml CFA. Pertussis 
toxin was given i.v. (150 ng per mouse) at the 
time of immunization and 48 h later. Fullerene 
ABS-75 (30 μg/kg, i.p.) was given daily beginning 
on day 20. n = 10 animals per group. Vehicle 
consisted of 2% DMSO. (C) Fullerene ABS-75 
(30 μg/kg, i.p.) and memantine (1.5 mg/kg) were 
given daily beginning on day 19. n = 9–10 animals 
per group. Vehicle consisted of 2% DMSO. (D) 
Left: EAE was induced in 8-week-old SJL mice 
by s.c. immunization with 50 μg of PLP131–151 
peptide in 4 mg/ml CFA. Pertussis toxin was 
given i.v. (150 ng per mouse) at the time of 
immunization and 48 h later. Fullerene ABS-
75 (30 μg/kg, i.p.) and memantine (1.5 mg/kg) 
were given daily beginning on day 17. n = 15 
animals per group. Arrows indicate relapses fol-
lowing the first attack. Right: Fullerene ABS-75 
treatment (30 μg/kg, i.p.) begun 1 day before 
MOG immunization and done on a daily basis 
until the end of disease course was not able to 
ameliorate acute EAE in C57BL/6J mice. n = 8 
animals per group. Disease score measured as 
follows: 0, no signs of disease; 1, loss of tone in 
the tail; 2, hindlimb paresis; 3, hindlimb paraly-
sis; 4, tetraplegia; 5, moribund.
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There was interaction between fullerene treatment and disease 
duration (time), which means that the effect of the treatment was 
not the same over time. The fullerene treatment seemed to be more 
effective during the progressive phase of the disease. In addition, 
cumulative disease score was lower in the fullerene-treated group 
as compared with the vehicle-treated group (Table 1).
Disease progression in animals treated with the unsubstituted 
fullerene (fullerene core without the attached NMDA receptor 
antagonist) was identical to progression of vehicle-treated mice 
(Figure 1B), demonstrating that the addition of the NMDA recep-
tor antagonist to the fullerene was required for the effect of ABS-75. 
In addition, treatment with memantine given daily (1.5 mg/kg i.p.) 
beginning at day 20 until the end of disease course did not have 
an effect on EAE progression (Figure 1C). Taken together, these 
results demonstrate that combining antioxidant and anti-excito-
toxic properties in the same molecule was critical for the effect of 
ABS-75 in reducing disease progression.
Because NOD mice develop diabetes, we measured blood glucose 
levels at the end of the disease course and found no evidence of 
diabetes, which might have confounded our results. Specifically, 
the blood glucose levels for ABS-75 were 113.17 ± 16.53 mg/dl, and 
for control were 115.5 ± 35.46 mg/dl. These results are consistent 
with the well-recognized observation that NOD mice immunized 
with CFA do not develop diabetes (37, 38).
We then tested fullerene ABS-75 in 2 traditional relapsing EAE 
models, the relapsing-remitting SJL model induced with PLP131–151 
and the monophasic relapsing C57BL/6J model induced with 
MOG. For the SJL relapsing-remitting model, we initiated treat-
ment with ABS-75 at the same time as in our NOD model (days 
17–20) and as a control, we also treated these animals with 
memantine. As shown in Figure 1D, in SJL mice immunized with 
PLP131–151 the first sign of disease began at days 9–10, and the peak 
of the first attack occurred at day 14. The disease score for the first 
attack was 2–2.5, which is more severe than what was observed in 
the NOD MOG model. After remission from the first attack, the 
animals had 2 subsequent relapses that were much less severe. The 
animals did not progress in terms of disability, as we observed in 
the progressive NOD model. Furthermore, as shown in Figure 1D, 
we did not observe an effect of ABS-75 (or memantine) as mea-
sured by clinical progression. Consistent with the clinical data, we 
did not observe prominent axonal loss in the SJL mouse model as 
we did in the NOD model (discussed below).
Finally, we tested whether fullerene ABS-75 treatment initi-
ated before immunization had an effect on monophasic MOG-
induced EAE in C57BL/6J mice. As shown in Figure 1D, fuller-
ene ABS-75 treatment (30 μg/kg i.p.) begun 1 day before MOG 
immunization and given on a daily basis until the end of disease 
course did not affect acute EAE in C57BL/6J mice. Thus, fuller-
ene ABS-75 only has an effect on the progressive clinical compo-
nent unique to the NOD model.
Reduced EAE progression in fullerene ABS-75–treated animals is accom-
panied by decreased axonal and myelin loss in the spinal cord. Axonal loss 
and demyelination were assessed by Bielschowsky’s silver staining 
and Luxol fast blue, respectively, in the spinal cord of vehicle- and 
fullerene ABS-75–treated animals at the end of the experiment 
and also in animals just after the first peak (day 23). Spinal cords 
from NOD mice analyzed after the first peak (day 23) showed only 
mild demyelination and virtually no axonal loss as determined by 
Bielschowsky’s silver staining, demonstrating that the first attack 
is not associated with significant axonal injury (data not shown). 
However, after disease progression, we observed pronounced axonal 
loss (Figure 2A) and demyelination (Figure 2B) in the spinal cord of 
vehicle-treated animals. In contrast, axonal loss and demyelination 
were strikingly reduced in fullerene ABS-75–treated animals, con-
sistent with our clinical observations. Neurofilament H staining, 
which identifies smaller nerve fibers, also revealed that fullerene 
ABS-75 treatment was capable of reducing axonal loss after disease 
progression. As shown in figure 2C, there was a reduction of neuro-
filament H staining (percentage of the area within the ventral col-
umn of the white matter stained for neurofilament H) in controls 
(3.96% ± 1.43%) compared with ABS-75 (16.13% ± 5.13%; P < 0.01). 
We also examined the brain and found perivascular inflamma-
tion, as was observed in relapsing EAE models (see Supplemental 
Figure 3; supplemental material available online with this article; 
doi:10.1172/JCI33464DS1), which was less than that seen in the 
spinal cord. We focused our pathological analysis on the lumbar 
region of the spinal cord because clinical disease in the NOD model 
(which is restricted to the tail and hindlimbs) is associated with 
prominent axonal loss in spinal cord but not in the brain.
We then assessed axonal loss in the traditional SJL relapsing-
remitting mouse model. Unlike the progressive NOD model, we 
did not observe significant axonal loss in the spinal cord of SJL 
animals at the end of the disease course (Figure 2D) and there was 
no effect of treatment with fullerene ABS-75 (data not shown). 
These results demonstrate that the progressive NOD model is 
unique both clinically and pathologically as compared with tradi-
tional relapsing-remitting EAE models.
Fullerene ABS-75 treatment blocks oxidative stress and diminishes 
CD11b infiltration into the white matter of the spinal cord in chronic pro-
gressive EAE. It was previously reported that fullerene derivatives 
were able to inhibit macrophage iNOS activity (39). In addition, 
studies have shown that fullerene increases SOD activity in LPS-
treated microglia (40). Since inflammation-induced oxidative 
stress is thought to be involved in the neurodegenerative compo-
Table 1
Fullerene ABS-75 treatment reduces disease progression in secondary progressive EAE
Groups	 Disease	score	above	1.5	 Mid-phase	 Secondary	progressive	 Cumulative	score
	 	 Mean	disease	score	 Mean	disease	score
	 	 Day	31	 Day	38	 Day	70	 Days	21–70
ABS-75 4/10 0.60A 0.65A 1.40A 49.8A
C60 8/10 1.15 1.45 2.45 81.0
Control 8/10 1.50 1.40 2.30 81.6
AP < 0.01 compared with control.
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nent of progressive EAE, we asked whether fullerene ABS-75 would 
interfere with NO production by activated microglia, which could 
at least partly explain its ability to reduce disease progression. To 
address this, we stimulated a murine microglial cell line with pep-
tidoglycan (TLR2 ligand) plus IFN-γ in the presence or absence 
of fullerene ABS-75. As shown in Supplemental Figure 1, in vitro 
fullerene ABS-75 did not affect TLR2-triggered microglial NO 
production. However, fullerene ABS-75 treatment initiated after 
disease onset halted CD11b infiltration into the white matter of 
the spinal cord in EAE. Hematoxylin and eosin staining performed 
on spinal cord sections from NOD mice followed for EAE for 70 
days revealed an intense inflammatory infiltrate associated with 
disease progression. To identify the cells comprising the infil-
trate, we stained for different markers and found large numbers 
of CD11b+ cells infiltrating the white matter of the vehicle-treated 
animals (Figure 3A). Interestingly, only very few CD3+ T cells were 
observed in the spinal cord of animals with chronic progressive 
EAE (data not shown). As shown in Figure 3A, numbers of CD11b 
cells were dramatically diminished in the spinal cord of fullerene 
ABS-75–treated mice. Because infiltrating CD11b cells may be an 
Figure 2
Fullerene ABS-75 treatment diminishes axonal loss and demyelination in secondary progressive EAE. (A) Bielschowsky’s silver impregnation 
for axons showed a reduction of axonal density in the white matter of the spinal cord (arrows) of a vehicle-treated mouse as compared with 
ABS-75–treated animal. The axonal pathology analysis was performed after disease progression at the end of the disease course. Original 
magnification, ×50 (top panels); ×100 (bottom panels). Quantification of stained spinal cord sections by image analysis (ImageJ; NIH) confirmed 
a reduction in axonal loss when comparing ABS-75– and vehicle-treated animals. P < 0.02; Student’s t test, mean ± SD. (B) Luxol fast blue stain-
ing showed a reduction in the myelin content in the white matter of the spinal cord (arrows) of vehicle-treated mice as compared with ABS-75– 
treated animals. Original magnification, ×50 (top panels); ×100 (bottom panels). Quantification of stained spinal cord sections showed a reduc-
tion in demyelination when comparing ABS-75– and vehicle-treated animals. P < 0.01. Student’s t test, mean ± SD. (C) Neurofilament H 
staining, which identifies smaller nerve fibers (depicted in red; white arrows) shows reduction in nerve fiber density (percentage of the area 
within the ventral column of the white matter stained for neurofilament H) in controls (3.96% ± 1.43%) versus ABS-75 (16.13% ± 5.13%). 
P < 0.01; Student’s t test, mean ± SD. Nuclei of infiltrating cells stained blue (yellow arrows), and GFAP stained green. Original magnification, 
×400. (D) Bielschowsky’s silver impregnation for axons showed no significant reduction of axonal density in the white matter of the spinal cord 
of SJL mice at the end of the disease course as compared with naive animals. Original magnification, ×100.
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important source of molecules causing oxidative damage during 
progressive EAE, we performed staining for nitrated proteins to 
investigate whether reduction of CD11b infiltration in fullerene-
treated mice was associated with less oxidative injury. Protein 
tyrosine nitration may result from peroxynitrite action, which is 
formed by NO reacting with superoxide anion (41, 42). As shown 
in Figure 3B, while we observed intense staining for nitrotyrosine 
in vehicle-treated animals, protein tyrosine nitration was virtually 
absent in the spinal cords from fullerene ABS-75–treated mice. 
Oxidative injury as measured by nitrotyrosine staining in vehicle-
treated animals was associated with hyperreactive astrocytes (Fig-
ure 3B). These results demonstrate that fullerene ABS-75 treat-
ment blocked CD11b infiltration and oxidative injury in the spinal 
cord of EAE NOD mice.
Fullerene ABS-75 treatment is associated with decreased CCL2 expression 
by astrocytes. Since astrocyte-derived CCL2 is the main chemokine 
attracting CD11b+ cells to the CNS in EAE (43, 44), we investi-
gated the expression of CCL2 following treatment with ABS-75. As 
shown in figure 3C, we found large numbers of CCL2-expressing 
cells in vehicle-treated animals after disease progression. In con-
trast, CCL2-expressing cells were virtually absent in mice receiving 
the fullerene ABS-75. Double staining carried out to identify which 
cells were expressing CCL2 revealed that although there were occa-
sional CD11b cells that were CCL2+ (data not shown), most CCL2-
expressing cells in the spinal cord of control mice were astrocytes 
(Figure 3D). The merged image in Figure 3D shows colocalization 
of CCL2- and GFAP-expressing cells. Association between inflam-
mation and CCL2 production by astrocytes could be observed in 
the white matter of control mice, where we found a large number 
of infiltrating cells (blue nuclei) adjacent to proliferating astrocytic 
processes (GFAP in red) highly expressing CCL2 (Figure 3D). This 
further suggests that in control animals the CD11b infiltration is 
associated with astrocyte-derived CCL2.
Next we performed in vitro experiments to test the possibility 
that fullerene ABS-75 acts directly on astrocytes to block CCL2 
expression. Primary cultures of mouse astrocytes were stimulated 
in vitro with LPS and IFN-γ in the presence or absence of fullerene 
ABS-75 (1 μM). The supernatants were collected at 24 h and mea-
sured for CCL2 by ELISA. As shown in Supplemental Figure 2, 
LPS/IFN-γ treatment induced CCL2 production on primary 
Figure 3
Fullerene ABS-75 treatment halts oxidative injury, blocks CCL2 production by astrocytes, and reduces CD11b infiltration into the spinal cord of 
secondary progressive EAE mice. (A) CD11b staining revealed large numbers of CD11b+ cells infiltrating the ventral column (arrows) of vehicle-
treated control animals, which was almost absent in mice that received the fullerene ABS-75 treatment. Original magnification, ×200. Quantifica-
tion confirmed reduced CD11b+ cells infiltrating the spinal cord in ABS-75–treated animals with progressive EAE. P < 0.007; Student’s t test, 
mean ± SD. (B) Intense staining for nitrotyrosine (stained red; white arrows) in the spinal cord of vehicle-treated mice after disease progression 
indicated occurrence of oxidative injury, which was absent in ABS-75–treated animals. The presence of hyperreactive astrocytes (GFAP, stained 
green, yellow arrows) was associated with oxidative injury in vehicle-treated animals. Original magnification, ×200. (C) CCL2 staining demon-
strated a large number of cells expressing CCL2 in the spinal cord of control animals after disease progression, whereas CCL2-positive cells 
were virtually absent in animals treated with fullerene ABS-75. Original magnification, ×100. (D) Triple staining performed on the spinal cord of 
control mice revealed high CCL2 expression (green) by astrocytic processes (GFAP, shown in red) in inflamed (blue nuclei of infiltrating cells) 
regions of the white matter. This demonstrates that in control animals, infiltration of inflammatory cells is associated with astrocytic expression 
of CCL2. Original magnification, ×400.
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murine astrocytes that was not blocked by ABS-75. These results 
indicate that although fullerene ABS-75 does not directly act on 
astrocytes, in vivo treatment downregulates CCL2 expression by 
astrocytes, which appears to explain the reduction in CD11b infil-
tration in the spinal cord of fullerene ABS-75–treated animals.
Fullerene ABS-75 protects neurons from oxidative and glutamate-
induced injury. Due to imbalanced glutamate metabolism and the 
consequent increase in its extracellular concentration, glutamate-
induced excitotoxicity is thought to be a major cause of axonal 
damage in MS and EAE. In fact, it has been demonstrated that 
glutamate receptor antagonists and inhibitors of glutamate trans-
mission were efficient in reducing death of oligodendrocytes and 
ameliorating clinical EAE (15–18, 45). NMDA-induced neuronal 
injury has also been shown to induce CCL2 expression by astro-
cytes in organotypic brain cultures (46, 47). Since fullerene ABS-75 
bears a moiety known to work as an NMDA receptor antagonist, 
we asked whether it would be able to protect neurons from gluta-
mate- and H2O2-induced injury. In order to answer this question, 
rat cortical neurons were challenged with 60 μM H2O2 or 50 μM 
glutamate for 24 h in the absence or presence of ABS-75 (1 μM) or 
MK801 (1 μM). Glutamate- and H2O2-induced injury was assessed 
by MAP-2 staining and lactate dehydrogenase (LDH) activity as 
an indicator of cell viability. MK801, which is an NMDA receptor 
antagonist with known neuroprotective properties (12, 48), was 
used as a positive control. As shown in Figure 4, A and B, we found 
that fullerene ABS-75 possesses neuroprotective properties and 
inhibits glutamate excitotoxicity. Thus, after glutamate (50 μM) 
and H2O2 (60 μM) challenge, we observed more MAP-2 staining 
(Figure 4A) and lower LDH activity (Figure 4B) in the neuronal 
cultures treated with fullerene ABS-75 as compared with control.
Fullerene ABS-75 does not impair memory function. In humans, 
NMDA receptor antagonists are reported to produce side effects 
such as drowsiness, hallucinations, psychosis, memory impair-
ment, and vomiting (49, 50). In animals, NMDA receptor blockade 
by MK801 is also accompanied by memory and learning impair-
ment (51, 52). The side effects of glutamatergic blockade have led 
some stroke clinical trials to be discontinued. We did not observe 
any obvious toxic effects or behavioral changes in our animals, 
even after treating them for more than 40 days. To directly address 
memory function, we performed behavioral experiments on 
ABS-75–treated animals as compared with MK801-treated mice. 
For these experiments, each mouse was placed at the end of an 
open arm facing away from the central platform of a plus maze 
apparatus. The transfer latency, i.e., the time each mouse took to 
move from the open arm to either enclosed arm was measured on 
day 1, and this was the acquisition trial. On day 2, which was the 
Figure 4
Fullerene ABS-75 protects neurons from oxidative injury and NMDA-dependent glutamate-induced injury but does not impair mouse memory 
function. Rat cortical neurons (11 DIV) were challenged with either 60 μM H2O2 or 50 μM glutamate for 24 h in the absence or presence of 
ABS-75 (1 μM) or MK801 (1 μM). Glutamate- and H2O2-induced injuries were assessed by (A) MAP-2 staining and (B) LDH activity. The 
results showed reduced neuronal damage in fullerene ABS-75– and MK801-treated cultures. P < 0.01, control versus ABS-75 and MK801, 
and ABS-75 versus MK801. P < 0.01, control versus ABS-75, and control versus MK801 (H2O2-induced injury). ANOVA followed by post-hoc 
test, mean ± SD. (C) Fullerene ABS-75 and MK801 effects on memory function were assessed on a plus maze apparatus. On the first day 
(acquisition trial), animals were placed at the edge of an open arm and the latency to the first entry in the central area was recorded. On the 
second day (retention trial), all animals were returned to the arena and the latency to the first transfer onto the central area was recorded. 
Drugs were administered i.p. 30 min before the retention trial. All animals moved to the central area in the acquisition trial. In the retention trial, 
only animals treated with 0.15 mg/kg MK801 had similar results to those of vehicle mice in the acquisition trial. Animals treated with PBS, 2% 
DMSO, or ABS-75 arrived at the central area faster in the retention trial than in the acquisition trial, indicating that, unlike MK801, fullerene 
ABS-75 does not impair memory function. P < 0.05, Kruskal-Wallis test followed by Dunn’s multiple comparisons test. n = 10 animals per 
group. Median (line through each box) ± SD (error bars) are shown. Original magnification, ×130.
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retention trial, animals were injected either with PBS, 2% DMSO, 
MK801 (150 μg/kg), or fullerene ABS-75 (30 μg/kg) and after 
30 min tested for memory function as measured by their trans-
fer latency time. As shown in figure 4C, the transfer latency time 
observed in PBS- and DMSO-treated mice significantly decreased 
when comparing acquisition and retention trials, indicating that 
animals could remember how to escape from the unpleasant 
situation represented by the open arm. Animals receiving fuller-
ene ABS-75 also presented lower transfer latency time across tri-
als and thus did not differ from PBS- and DMSO-treated mice. 
Figure 5
Fullerene ABS-75 rescues the reduced expression of EAAT1 and GS that occurs in astrocytes under inflammatory conditions. (A) Primary mouse 
astrocytes were stimulated with either TNF-α (50 ng/ml) or LPS (1 μg/ml) and IFN-γ (200 U/ml) for 24 h in the absence or presence of ABS-75 
(1 μM) or MK801 (1 μM). GS and EAAT1 expression were assessed by western blot. Quantification was performed using densitometry analysis 
(ImageJ; NIH) for 2 independent experiments. We found that both ABS-75 and MK801 could reverse the reduced expression of EAAT1 and GS 
by astrocytes under inflammatory conditions. P < 0.01, ANOVA followed by post-hoc test, mean ± SD. (B) Immunohistochemistry performed on 
spinal cord sections analyzed after disease progression revealed increased GS expression within the white matter of fullerene ABS-75 group as 
compared with vehicle-treated animals. Quantification by ImageJ confirmed increased numbers of GS-expressing glial cells in the white matter 
of fullerene ABS-75–treated mice. P < 0.05, Student’s t test, mean ± SD. (C) Immunohistochemistry performed on spinal cord sections analyzed 
after disease progression revealed that the cells expressing GS within the white matter were either oligodendrocytes (CNPase positive) or astro-
cytes (GFAP positive). Original magnification, ×200 (B); ×630 (C).
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In contrast, MK801-treated mice did not improve their perfor-
mance across acquisition and retention trials and presented 
increased transfer latency time in the retention trial as compared 
with PBS- and DMSO-treated animals. These results indicate that, 
unlike MK801, fullerene ABS-75 does not impair memory func-
tion as measured in the animal model.
Fullerene ABS-75 rescues astrocytic glutamate-buffering ability by revers-
ing decreased glutamine synthetase and glutamate transporter expression 
under inflammatory conditions. Since the glutamate released in 
synaptic clefts is taken up by astrocytes and then converted into 
nontoxic glutamine by the glia-specific enzyme glutamine syn-
thetase (GS), astrocytes are considered to be important cells that 
keep extracellular glutamate concentrations low within the CNS 
and thereby avoid neurotoxicity (53, 54). It has been shown that 
by enhancing iNOS, inflammatory stimuli lead to a decrease in 
GS activity (55), which may contribute to imbalanced glutamate 
metabolism and axonal damage in chronic inflammatory diseases 
such as MS. Compromised GS activity in astrocytes has been dem-
onstrated in EAE (56). NMDA receptor signaling also has been 
associated with decreased activity of GS in astrocytes (57). Reduced 
Figure 6
Fullerene ABS-75 treatment does not interfere with the adaptive compartment of the immune system. (A–C) Splenocytes from vehicle- and 
ABS-75–treated animals (4 per group) were harvested by the end of disease course and cultivated in the presence of MOG for (A) T cell pro-
liferation, (B) IL-2, and (C) IFN-γ production. No differences were observed. (D) Serum collected from vehicle- and ABS-75–treated animals at 
the end of disease course was tested for MOG-specific IgG2b levels. No differences were observed. (E and F) NOD mice were treated once 
a day with fullerene ABS-75 (30 μg/kg i.p.) from day –1 to day 10 after immunization, when draining lymph nodes were harvested to evaluate 
T cell recall response upon MOG stimulation. No differences were found for (E) T cell proliferation and (F) IFN-γ production. (G and H) NOD 
mice were immunized with MOG, and after 10 days, cells harvested from the draining lymph nodes were stimulated with antigen in the presence 
or absence of 1 μM fullerene ABS-75. In vitro 1 μM fullerene ABS-75 did not interfere with (G) T cell proliferation and (H) IFN-γ production upon 
antigen-specific stimulation.
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expression of glutamate transporters such as EAAT1 also contrib-
utes to the decreased astrocyte glutamate-buffering ability under 
inflammatory conditions. Indeed, it has been demonstrated that 
by releasing TNF-α, autoreactive T cells reduce EAAT1 expression 
and glutamate uptake in astrocytes (58). Since fullerene ABS-75 
has the potential to quench free radicals such as NO and block 
NMDA receptors, we investigated whether it can maintain the 
astrocyte glutamate-buffering ability under inflammatory con-
ditions. Primary murine astrocytes were challenged with either 
TNF-α (50 ng/ml) or LPS (1 μg/ml) and IFN-γ (200 U/ml) for 24 h 
in the presence or absence of ABS-75 (1 μM) or MK801 (1 μM). GS 
and EAAT1 expression were assessed by western blot. As shown 
in Figure 5A, fullerene ABS-75 reversed the reduced expression of 
both EAAT1 and GS that occurs under inflammatory conditions 
and thus maintained astrocyte glutamate-buffering ability.
Since fullerene ABS-75 treatment initiated after disease onset 
was able to block CD11b infiltration and oxidative injury in the 
spinal cord of EAE mice, we asked whether the treatment would 
also prevent downregulation of GS expression by glial cells after 
disease progression. Immunohistochemistry performed on spinal 
cord sections analyzed after disease progression revealed reduced 
GS expression by glial cells within the white matter of control 
group as compared with fullerene-treated animals (Figure 5B). 
Double staining demonstrated the expression of GS in both oli-
godendrocytes (CNPase positive) and astrocytes (GFAP positive) 
(Figure 5C). The increased frequency of GS-expressing cells was 
the same for both oligodendrocytes and astrocytes.
Fullerene ABS-75 treatment does not affect adaptive T and B cell 
responses. In order to determine whether fullerene ABS-75 treat-
ment affected immunologic responses, we first compared antigen-
specific T cell responses of vehicle- and fullerene ABS-75–treated 
animals at the end of disease course. As shown in Figure 6, A–C, 
there was no difference in T cell proliferation or cytokine (IFN-γ 
and IL-2) production upon antigen-specific stimulation between 
vehicle- and fullerene-treated groups. Also, there was no difference 
in serum MOG-specific IgG2b levels (Figure 6D). Next, we asked 
whether fullerene ABS-75 treatment initiated before immuniza-
tion would interfere with T cell recall response upon antigenic 
stimulation. We treated NOD mice once a day with fullerene ABS-
75 (30 μg/kg i.p.) from day –1 to day 10 after immunization, at 
which time draining lymph nodes were harvested. As shown in 
Figure 6, E and F, T cell proliferation and IFN-γ production upon 
MOG stimulation were not affected by fullerene ABS-75 treat-
ment initiated before immunization. We also investigated T cell 
recall response in the presence of fullerene ABS-75. NOD mice 
were immunized with MOG, and after 10 days, cells harvested 
from the draining lymph nodes were stimulated with antigen in 
the presence or absence of 1 μM fullerene ABS-75. Fullerene ABS-
75 did not interfere with T cell proliferation and cytokine pro-
duction upon antigenic-specific stimulation (Figure 6, G and H). 
Altogether, these results demonstrate that fullerene ABS-75 does 
not affect adaptive T cell autoimmune responses in EAE.
Discussion
Understanding the mechanisms leading to cumulative neurologi-
cal disability in patients with MS and further developing effective 
therapeutic strategies aimed at reducing disease progression is a 
major goal in MS research. Treatments aiming at only blocking 
the inflammatory component of the disease have not been success-
ful reducing neurological disability in SP-MS patients (59, 60) and 
in chronic EAE models (61), thus pointing out the necessity for 
new therapeutic approaches. In the past few years, several studies 
have contributed to the evolving concept that disease progression 
in SP-MS is closely related to neurodegeneration and axonal loss 
(4–6). In this study we used the water-soluble fullerene derivative 
ABS-75 as a new therapeutic approach aimed at neuroprotection 
and ultimately at reducing disease progression and neurological 
disability in a chronic progressive EAE model.
We investigated the effect of ABS-75 in a progressive NOD EAE 
model induced with MOG peptide. This model is different from 
the traditional relapsing-remitting SJL and C57BL/6J models, 
which do not demonstrate the chronic clinical progression or 
prominent axonal loss in the spinal cord observed in the NOD 
progressive EAE model. Biozzi mice have been used as a model of 
chronic EAE, though they do not exhibit clinical progression as 
in the NOD model (18). The model we have employed is ideally 
suited to investigate mechanisms and therapies relevant to SP-MS, 
which involves chronic progressive spinal cord dysfunction. 
Immune-modulating drugs for relapsing MS that effectively treat 
traditional relapsing EAE models are not of benefit in the second-
ary progressive form of MS. No effect of ABS-75 was observed 
in the SJL and C57BL/6J relapsing models, which do not have a 
clinical and pathologic progressive component. This observation 
suggests that different mechanisms are involved in the 2 stages 
of disease and that therapies with different modes of action are 
needed to treat SP-MS. Thus, we believe we have not only identi-
fied a novel approach for the treatment of SP-MS, but have also 
characterized a new animal model for the investigation of the sec-
ondary progressive form of MS.
Our results demonstrate that combining antioxidant and 
anti-excitotoxic properties in the same molecule is critical for 
the effect of ABS-75 in reducing neurodegeneration and disease 
progression in the NOD EAE model. In fact, treatment with the 
unsubstituted fullerene (fullerene core without the attached 
NMDA receptor antagonist) or with memantine alone had no 
effect on disease progression.
It has been suggested that excitotoxicity due to imbalanced glu-
tamate metabolism and consequent increased extracellular gluta-
mate concentration is one important mechanism by which neu-
rodegeneration occurs in MS (19). Indeed, it has been shown that 
cerebrospinal fluid glutamate levels are increased during relapses 
in RR-MS patients and highly increased in SP-MS patients who 
had an increase of at least 1 point in the EDSS score during the last 
6 months as compared with SP-MS patients without any change 
in the EDSS score (13, 62). Accordingly, it has been demonstrated 
that glutamate receptor antagonists and inhibitors of glutamate 
transmission were efficient in reducing axonal damage, death 
of oligodendrocytes, and ameliorating clinical EAE (15–19, 45). 
Extracellular glutamate levels within the CNS are tightly regulated 
(53, 54), and the increase of these levels is well known to cause neu-
rodegeneration through NMDA receptor signaling (9, 19, 63, 64). 
Because fullerene ABS-75 bears a moiety that possesses the ability 
to block NMDA receptors, we tested whether it would directly pro-
tect primary neurons in culture from glutamate-induced injury. 
Our results showed that indeed ABS-75 confers neuroprotection 
and reduces in vitro excitotoxicity, suggesting this could be one of 
the mechanisms by which fullerene ABS-75 diminishes axonal loss 
and reduces disease progression in the NOD EAE model.
Imbalanced glutamate metabolism in MS is likely to occur, at 
least in part because under inflammatory conditions there is a 
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decrease in the expression of glutamate transporters and GS in 
astrocytes (55, 56, 58). Glutamate transporters such as EAAT1 
are required for glial cells to uptake extracellular glutamate, and 
GS is a glial-specific enzyme responsible for the conversion of 
glutamate into nontoxic glutamine. Full expression and activity 
of EAAT1 and GS are needed for astrocytes to efficiently buffer 
extracellular glutamate. (53, 54). Since increased iNOS activity and 
glutamate itself have been implicated as being responsible for the 
downregulation of GS expression by astrocytes under inflamma-
tory insult (55, 57), we tested whether fullerene ABS-75 would res-
cue the glutamate-buffering ability of primary murine astrocytes 
in culture. As already mentioned, ABS-75 has a great potential to 
quench free radicals and block NMDA receptors. Our results show 
that in vitro fullerene ABS-75 reversed the reduced GS and EAAT1 
expression by astrocytes under inflammatory conditions. In addi-
tion, immunohistochemistry performed on spinal cord sections 
analyzed after disease progression revealed that fullerene ABS-75 
treatment also rescued GS expression in the white matter of mice 
with chronic progressive EAE. Altogether, our data suggest that 
fullerene ABS-75 treatment prevents excitotoxicity directly by 
blocking NMDA signaling in neurons, and indirectly by correcting 
imbalanced glutamate metabolism within the CNS, thus avoiding 
axonal loss and disease progression.
Neuronal injury caused by excitotoxicity has been shown to 
induce CCL2 production by astrocytes (46, 47). Although we 
did not observe any direct effect of fullerene ABS-75 on LPS-
induced CCL2 expression by primary astrocytes in culture, 
immunohistochemistry demonstrated that fullerene ABS-75 
completely blocked CCL2 production in the spinal cord of ani-
mals with chronic progressive EAE. We believe it is possible that 
by blocking excitotoxicity and axonal damage, fullerene ABS-75 
treatment was also able to indirectly prevent in vivo CCL2 produc-
tion by astrocytes. CCL2 has been described as a major chemokine 
attracting monocytes/macrophages to EAE and MS lesions (43, 
44). Thus, it is likely that as a consequence of CCL2 production 
blockade, fullerene ABS-75 reduced CD11b inflammation in the 
white matter of chronic progressive EAE mice. Indeed, consistent 
with the observed reduced CCL2 expression, much less CD11b+ 
cells were found in the white matter of fullerene ABS-75–treated 
mice after disease progression.
Monocytes or migrating macrophages comprising the CD11b+ 
population are described as an important source of molecules 
involved in oxidative injury during EAE and MS (65, 66). Because 
peroxynitrite formed by the reaction between NO and superoxide 
anion can lead to protein tyrosine nitration (41, 42), we utilized 
staining for nitrotyrosine as a marker for oxidative injury in chronic 
progressive EAE. Our results showed that the reduction in the 
CD11b infiltration is accompanied by less oxidative injury in the 
spinal cord of fullerene ABS-75 treated mice. Thus, besides block-
ing CD11b infiltration, fullerene ABS-75 treatment also blocks 
oxidative injury associated with the inflammatory response.
Based on our results, pathogenesis of chronic progressive EAE 
in the NOD model employed here appears to involve a self-per-
petuating cycle in which the initial autoimmune inflammatory 
response triggers glutamate imbalanced metabolism that causes 
neuronal injury and axonal loss by excitotoxicity, which in turn 
induces the production of CCL2 by astrocytes. CCL2 production 
is responsible for augmenting CD11b inflammation with conse-
quent further increase of oxidative injury, which in turn leads to 
further imbalance of glutamate metabolism by downregulating 
GS and probably glutamate transporters in glial cells. Our results 
suggest that fullerene ABS-75 is effective at reducing disease pro-
gression because it is able to break this self-perpetuating cycle by 
preventing glutamate-imbalanced metabolism and also by directly 
blocking NMDA signaling–dependent glutamate-induced injury.
Treatments that block NMDA-dependent glutamatergic trans-
mission can lead to undesirable side effects such as drowsiness, 
hallucinations, psychosis, memory impairment, and vomiting 
(49, 50). In animals, NMDA receptor blockade by MK801 is also 
accompanied by memory and learning impairment (51, 52). Such 
side effects have led several selective NMDA antagonists to fail 
in clinical trials, pointing to the need for agents that are able to 
modulate glutamatergic transmission but are clinically tolerable. 
The adamantyl moiety present in fullerene ABS-75 structure is 
chemically related to memantine, which has been characterized 
as a therapeutic safe NMDA antagonist due to features such as 
moderate potency, strong voltage dependence, and fast block-
ing/unblocking kinetics (67, 68). We compared the performance 
of MK801- and fullerene ABS-75–treated animals on a memory 
task and observed that, unlike MK801, fullerene ABS-75 does not 
cause any impairment of memory function. The data suggest that 
fullerene ABS-75 treatment is not likely to cause side effects due to 
blockade of physiologically glutamatergic transmission.
We performed a series of experiments to assess possible effects 
of fullerene ABS-75 on the adaptive compartment of the immune 
system. We could not detect any in vitro or ex vivo effect of fuller-
ene ABS-75 on T cell function upon antigenic stimulation. Fuller-
ene ABS-75 in vivo treatment begun before immunization also did 
not interfere with acute EAE in MOG-immunized C57BL/6J mice. 
Thus, we do not believe fullerene ABS-75 reduces disease progres-
sion in chronic progressive EAE by acting on the adaptive com-
partment of the immune system.
Development of receptor-specific therapy for treatment of CNS 
disorders is an important therapeutic goal. By targeting an anti-
oxidant molecule to the NMDA receptor, we have developed a 
new therapeutic strategy for blocking excitotoxicity and oxidative 
injury in the CNS. This approach prevents axonal loss and reduces 
neurological disability in a model of SP-MS and is applicable to 
other neurodegenerative diseases and primary progressive forms 
of MS as well.
Methods
Animals and induction of EAE. SJL, NOD, and C57BL/6J mice were purchased 
from Taconic or The Jackson Laboratory. EAE was induced by subcutaneous 
immunization of 10-week-old NOD mice or 7-week-old C57BL/6J into the 
flanks with 200 μl of an emulsion containing 150 μg of MOG35–55 peptide 
(MEVGWYRSPFSRVVHLYRNGK; David Teplow, David Geffen School of 
Medicine, UCLA, Los Angeles, California, USA) and 400 μg of Mycobacterium 
tuberculosis extract H37 Ra (Difco) in incomplete Freund’s adjuvant oil. In 
addition, the animals received 150 ng of pertussis toxin (List Biological Lab-
oratories) i.p. on day 0 and day 2. EAE in SJL mice was induced by immuniza-
tion with 50 μg of PLP131–151 peptide in complete Freund’s adjuvant. Clinical 
signs of EAE were assessed according to the following score: 0, no signs of 
disease; 1, loss of tone in the tail; 2, hindlimb paresis; 3, hindlimb paralysis; 
4, tetraplegia; 5, moribund. Animals were kept in a conventional pathogen-
free facility at the Harvard Institutes of Medicine, and all experiments were 
carried out in accordance with guidelines prescribed by, and were approved 
by, the standing committee of animals at Harvard Medical School.
Cytokines and T cell proliferation assays. Splenocytes and lymph node cells 
were cultured in X-VIVO medium and plated at 5 × 105 cells per well in the 
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presence of MOG35–55 for 72 h. For some experiments, lymph node cells were 
cultured in the presence of 1 μM fullerene ABS-75. During the last 16 h, 
cells were pulsed with 1 μCi of [3H]-thymidine (PerkinElmer) followed by 
harvesting on glass fiber filters and analysis of incorporated [3H]-thymi-
dine in a b-counter (1450 Microbeta, Trilux; PerkinElmer). Supernatants 
were collect after 40 h of culture for cytokine measurements by ELISA.
CCL2, EAAT1, and GS expression in primary murine astrocytes. Primary 
murine astrocytes (>95% GFAP positive) prepared by standard methodol-
ogy were stimulated in vitro with TNF-α (50 ng/ml) or LPS (1 μg/ml) and 
IFN-γ (100 U/ml) in the presence or absence of 1 μM fullerene ABS-75. The 
supernatants from astrocyte cultures were collected at 24 h and measured 
for CCL2 by ELISA. GS and EAAT1 expression was assessed by western 
blot on astrocyte culture lysates. Protein concentration in each sample 
was determined using a bicinchoninic acid kit (BCA-1; Sigma-Aldrich), 
and after dilutions to standardize the samples, the same amount of pro-
tein was loaded into a polyacrylamide gel (NuPAGE Novex 12% Bis-Tris 
Gel; Invitrogen) for protein separation. The samples were transferred to 
nitrocellulose membranes (Amersham), and after 1 h blocking (blocking 
buffer; Pierce Biotechnology), the membranes were incubated at 4°C over-
night with the primary antibody (rabbit anti-GS, G2781; Sigma-Aldrich; or 
rabbit anti-EAAT1, ab416; Abcam). As a secondary antibody, horseradish 
peroxidase–linked anti-rabbit IgG antibodies (Cell Signaling Technology) 
were used. Specific signals were visualized using the ECL detection sys-
tem (Amersham) with Fuji x-ray films (RX NIF). The optical density of 
the bands was estimated by determining the threshold of visibility using 
ImageJ software (NIH).
Neuronal injury evaluation. Primary neurons from the rat cortex (N200200; 
Genlantis) were seeded on 24-well poly-d-lysine/laminin–coated plates 
at 32 × 103 cells/cm2 and cultivated in neurobasal/B-27–supplemented 
medium for 10 days. On day 11, fully differentiated neurons were chal-
lenged either with 50 μM glutamate or 60 μM H2O2 for 24 h either in the 
presence or absence of the fullerene 1-μM ABS-75. Neuronal damage were 
assessed by staining for MAP-2 (M4403; Sigma-Aldrich), followed by Alexa 
Fluor 488–conjugated goat anti-mouse IgG (Invitrogen) and by measur-
ing LDH activity (CytoTox 96 Non-Radioactive Cytotoxicity Assay, G1780; 
Promega) as an indicator of cell viability.
Microglia cell culture. ATCC EOC 20 murine microglial cell line (CRL-
2469) was cultured in 70% ATCC DMEM, 10% fetal bovine serum, and 20% 
conditioned medium from LADMAC cell line (CRL-2420) and stimulated 
with peptidoglycan (TLR2 ligand) plus IFN-γ in the presence or absence of 
different concentrations of fullerene ABS-75. TLR2-triggered microglial 
NO production was measured by Griess Reaction utilizing a Total NO/
Nitrite/Nitrate Assay (KGE001; R&D Systems).
Behavioral experiments. On day 1 (acquisition trial) each mouse was 
placed at the end of one open arm facing away from the central platform 
in a plus-maze apparatus. The transfer latency, i.e., the time each mouse 
took to move from the open arm to either enclosed arm, was measured. 
Memory retrieval was assessed on the second day (retention trial), when all 
animals returned to the arena and the transfer latency time was recorded 
again under the influence of PBS, 2% DMSO, MK801 (150 μg/kg), or 
fullerene ABS-75 (30 μg/kg), which were administered i.p. 30 min before 
the retention trial.
Immunohistochemistry.	Spinal cord tissue samples from MOG-immu-
nized NOD mice at the end of the disease course were collected, fixed in 
4% paraformaldehyde, cryoprotected in 20% sucrose, and frozen in OCT. 
Spinal cord frozen sections were cut at 10 μm and processed for histo-
logical analysis, immunohistochemistry, or immunofluorescence. Axo-
nal loss and demyelination were assessed by Bielschowsky’s silver stain-
ing and Luxol Fast Blue, respectively. CD11b cells were identified by 
immunohistochemistry utilizing rat anti-CD11b antibody (MCA711; Sero-
tec), followed by biotinylated goat anti-rat IgG (Jackson ImmunoResearch 
Laboratories) and standard avidin-biotin immunoperoxidase method 
(Vector Laboratories). The sections were counterstained with hematoxy-
lin. Immunofluorescence was employed to identify neurofilament H– 
positive nerve fibers (rabbit anti-neurofilament 200 antibody, N4142; 
Sigma-Aldrich), CCL2 expression (goat anti-CCL2 antibody, R&D systems, 
AF-479-NA), GS expression (rabbit anti-GS, G2781; Sigma-Aldrich), pro-
tein nitration (rabbit anti-nitrotyrosine antibody, N0409; Sigma-Aldrich), 
oligodendrocytes (chicken anti-CNPase antibody, ab53410; Abcam), and 
astrocytes (chicken anti-GFAP antibody, PCK-591P100; Covance Research 
Products Inc.; and rabbit anti-GFAP antibody, G9269; Sigma-Aldrich). 
Secondary antibodies were purchased from Molecular Probes: Alexa Fluor 
594–conjugated goat anti-rabbit IgG (A-11012), Alexa Fluor 488–conju-
gated goat anti-chicken IgG (A-11039), Alexa Fluor 488–conjugated don-
key anti-goat IgG (A-11055), and Alexa Fluor 594–conjugated donkey anti-
rabbit (A-21207). For image analysis, 2 or 3 lumbar spinal cord sections 
were selected according to regional landmarks from 3 different animals per 
group. Image analysis was performed using the software ImageJ (NIH). For 
quantification, level of labeling “threshold” was used as a cut-off to deter-
mine positive or negative staining. Data are expressed as mean ± SD.
Statistics. GraphPad Prism software (GraphPad Software Inc.) was uti-
lized throughout for statistical analysis. Two-way ANOVA analysis and 
Student’s t test were employed to analyze clinical disease score. Quantifica-
tion for axonal loss, demyelination, CD11b infiltration, neurofilament H, 
and GS expression were analyzed using the Student’s t test. ANOVA was 
employed to analyze LDH activity. Behavioral experiments were analyzed 
using Kruskal-Wallis ANOVA test followed by Dunn’s Multiple Compari-
sons test. P < 0.05 was considered significant.
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